Retour à la liste des essais cliniquesEye tumors / Uveal melanoma

IDE 196-002

IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator·s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2).

Ouvert à Paris depuis le : 07/10/2024
Public cible : Adult
Phase : Phase II/III

Description de l'essai

Phase 2a: To determine the;optimal dose of IDE196 +;crizotinib combination in Phase 2a;in order to achieve the;recommended dose for Phase 2b;and Phase 3;Phase 2b: To compare IDE196 +;crizotinib to investigatorÀs choice;of treatment with respect to PFS;per RECIST 1.1 as assessed by;blinded independent central review;(BICR)

Url of the trial

Investigateur principal

SOPHIE PIPERNO-NEUMANN

Médecin

Contacter